PPAR Research

PPARs: A Double-Edged Sword in Cancer Therapy?


Publishing date
01 Sep 2008
Status
Published
Submission deadline
01 Mar 2008

PPARs: A Double-Edged Sword in Cancer Therapy?

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 9469261
  • - Retraction

Retracted: Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

PPAR Research
  • Special Issue
  • - Volume 2008
  • - Article ID 350351
  • - Editorial

PPARs: A Double-Edged Sword in Cancer Therapy?

Dipak Panigrahy | Arja Kaipainen | ... | Sui Huang
  • Special Issue
  • - Volume 2008
  • - Article ID 750238
  • - Review Article

Combination Therapy of PPAR Ligands and Inhibitors of Arachidonic Acid in Lung Cancer

Jordi Tauler | James L. Mulshine
  • Special Issue
  • - Volume 2008
  • - Article ID 286249
  • - Review Article

The Role of NF-B in PPAR-Mediated Hepatocarcinogenesis

Howard P. Glauert | Karen Calfee-Mason | ... | Brett T. Spear
  • Special Issue
  • - Volume 2008
  • - Article ID 827096
  • - Review Article

The Role of PPAR Receptors and Leukotriene Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer

Thomas E. Adrian | Rene Hennig | ... | Xianzhong Ding
  • Special Issue
  • - Volume 2008
  • - Article ID 134059
  • - Review Article

PPARs Mediate Lipid Signaling in Inflammation and Cancer

Liliane Michalik | Walter Wahli
  • Special Issue
  • - Volume 2008
  • - Article ID 159415
  • - Review Article

Clinical Use of PPAR Ligands in Cancer

Jennifer L. Hatton | Lisa D. Yee
  • Special Issue
  • - Volume 2008
  • - Article ID 932632
  • - Review Article

PPAR, PTEN, and the Fight against Cancer

Rosemary E. Teresi | Kristin A. Waite
  • Special Issue
  • - Volume 2008
  • - Article ID 904251
  • - Review Article

The Role of PPARs in the Endothelium: Implications for Cancer Therapy

David Bishop-Bailey | Karen E. Swales
  • Special Issue
  • - Volume 2008
  • - Article ID 945275
  • - Review Article

PPAR and Agonists against Cancer: Rational Design of Complementation Treatments

Dorina Veliceasa | Frank Thilo Schulze-Hoëpfner | Olga V. Volpert
PPAR Research
 Journal metrics
See full report
Acceptance rate23%
Submission to final decision68 days
Acceptance to publication24 days
CiteScore4.900
Journal Citation Indicator0.770
Impact Factor4.385
 Submit

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.